Johnson & Johnson Tecvayli — Percent Change (as a percent) increased by 7.0% to 33.5% in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 151.9%, from 13.3% to 33.5%. This is a positive signal — higher values indicate stronger performance for this metric.
A positive percentage indicates accelerating sales momentum and market penetration, whereas a negative percentage suggests a deceleration in growth or potential market saturation.
This metric measures the period-over-period percentage growth or decline in net sales for the Tecvayli product line. It...
Comparable to year-over-year or quarter-over-quarter revenue growth rates for specific high-growth pharmaceutical products across the industry.
jnj_segment_tecvayli_percent_change_as_a_percent| Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|
| Value | 76.7% | 42.9% | 20.6% | 13.3% | 23.1% | 31.3% | 33.5% |
| QoQ Change | — | -44.1% | -52.0% | -35.4% | +73.7% | +35.5% | +7.0% |
| YoY Change | — | — | — | -82.7% | -46.2% | +51.9% | +151.9% |